Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why BioMarin's Shares Tumbled 11% in June

By Todd Campbell - Jul 9, 2016 at 10:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

M&A rumors failed to spark investor interest following the company's decision to shutter research on key Duchenne drugs.

Image source:Getty Images.

What: After failing to win over regulators in January, BioMarin Pharmaceuticals Inc. ( BMRN 0.85% ) discontinued development of four drugs in its pipeline targeting Duchenne muscular dystrophy, or DMD. The shuttering of research into exon-skipping therapies for DMD more than offset rumors that Sanofi SA ( SNY -0.75% ) could be considering a bid to buy the company, and as a result, BioMarin's shares slipped by 11% last month, according to S&P Global Market Intelligence.

So What: BioMarin acquired exon-skipping therapies in 2014 and filed for approval of the first of its exon-skipping drugs, Kyndrisa (drisapersen), shortly thereafter. Management had hoped that a big need for new therapies to treat this muscle-wasting disease could result in an FDA approval in spite of shaky efficacy in trials. However, the FDA ultimately opted against approval in January. On May 31, BioMarin threw in the towel on Kyndrisa and three other exon-skipping therapies in development, opting to focus its attention on other, more promising drugs in its rare-disease drug pipeline.

The news was disappointing to investors because many industry watchers thought that an approval of Kyndrisa could lead to annualized sales in the hundreds of millions of dollars and catapult BioMarin to profitability in 2017. Additionally, if Kyndrisa had been approved, it would have qualified BioMarin to receive a fast-track voucher that could be used to accelerate review times on other drugs in development. Alternatively, the company could have sold the voucher on the open market. In the past, similar vouchers have fetched more than $300 million.

As shares pulled back in June, rumors surfaced that Sanofi was mulling a bid to buy BioMarin. Sanofi is on the hunt to bulk up its product lineup, and drugs sold by BioMarin to treat rare diseases would conceivably complement Sanofi's rare-disease drug portfolio. In the first quarter, BioMarin's rare-disease drugs produced $237 million in revenue, while Sanofi's rare-disease drugs generated sales of $715 million, at current exchange rates.

Image source: BioMarin Pharmaceuticals Inc.

Now What: DMD was far from the only rare-disease indication being targeted by BioMarin, so while the discontinuation of development of exon-skipping drugs in its pipeline is a blow, it's not a deal-breaker. Exiting Q1, BioMarin's full-year sales guidance remains $1 billion, and even without tailwinds from Kyndrisa, management still hopes to turn a profit next year for the first time.

Among catalysts that could reignite BioMarin's shares are the potential filing for approval of pegvaliase for use in patients with phenylketonuria, or PKU. PKU is caused by a buildup of phenylalanine, an amino acid found in many foods, especially those high in protein. When phenylalanine builds up, it can cause mental, behavioral, neurological, and physical problems. About 50,000 people worldwide are diagnosed with PKU, and BioMarin expects to file for pegvaliase's approval before the end of this year.

As for the rumored mergers and acquisitions, it's unclear if there's any truth to the talk regarding Sanofi's interest. The likelihood that Sanofi could bid for BioMarin may have declined this week since it entered into a confidentiality agreement to kick the tires of Medivation, a cancer drug company. Earlier this week, new rumors emerged that Roche Holdings may be interested in buying BioMarin, but it's not clear if there's any truth to that rumor either.

Overall, BioMarin is an intriguing company with a slate of valuable drugs that target uncommon diseases. With its chance for profitability next year and new drugs making their way to market, investors ought to consider adding this company to their portfolios.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
$85.22 (0.85%) $0.72
Sanofi Stock Quote
$47.70 (-0.75%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.